SGLT2 inhibitors represent a newer wave of anti-lipotoxic medications, with recent studies finding that SGLT2 inhibitors decrease hepatic fat in patients with type 2 diabetes (Scheen, 2019; Sabine et al., 2020). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.